Teva Faces Laquinimod Setback After High Dose Linked To CV Events
This article was originally published in The Pink Sheet Daily
Teva will discontinue higher doses of laqunimod in two ongoing studies for multiple sclerosis after cardiovascular events were experienced in eight patients. Trials will continue with a lower dose.
Register for our free email digests: